Adjuvant Capecitabine Versus Observation Alone in Curatively Resected Stage IB Gastric Cancer((KCSG ST14-05): CATALYSIS

Summary

multi-center, prospective, randomized, open-label phase III

Conditions

• Gastric Cancer

Interventions

DRUG

capecitabine

capecitabine 1250 milligram (mg) / m² po bid (D1-14)

Sponsors & Collaborators

• Ulsan University Hospital

  collaborator OTHER

• Seoul National University Bundang Hospital

  collaborator OTHER

• Gangnam Severance Hospital

  collaborator OTHER

• Seoul National University Boramae Hospital

  collaborator OTHER

• Ajou University School of Medicine

  collaborator OTHER

• Chung-Ang University Hosptial, Chung-Ang University College of Medicine

  collaborator OTHER

• Hallym University Medical Center

  collaborator OTHER

• Inje University Haeundae Paik Hospital

  collaborator OTHER

• Kyung Hee University Hospital

  collaborator OTHER

• Gachon University Gil Medical Center

  collaborator OTHER

• Kangbuk Samsung Hospital

  collaborator OTHER

• Kyungpook National University Hospital

  collaborator OTHER

• Asan Medical Center

  lead OTHER

Principal Investigators

• Min-Hee Ryu, MD, PhD · Asan Medical Center

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

74 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2013-08-19

Primary Completion

2026-08-01

Completion

2026-08-01

Countries

• South Korea

Study Locations